Skip to main content
Premium Trial:

Request an Annual Quote

Danaher Prices €850M Senior Notes Offering

NEW YORK (GenomeWeb) – Danaher today said that its wholly owned subsidiary DH Europe Finance has priced an offering of €850 million ($947 million) in senior notes.

DH Europe is offering €250 million principal amount of floating rate senior notes due 2022 at an offering price of 100.147 percent of the principal amount. It also is offering €600 million principal amount of 1.2 percent senior notes due 2027 at an offering price of 99.682 percent of the principal amount.

Net proceeds are estimated to be around €845 million. Danaher said that about $560 million will go toward repaying all of the outstanding €500 million aggregate principal amount of Danaher International's Floating Rate Senior Notes due 2017, which mature on June 30, 2017. The remainder of the net proceeds will be used to repay outstanding commercial paper and for general corporate purposes.

The offering is expected to close on June 30.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.